{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:14:23Z","timestamp":1792005263222,"version":"4.4.0"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Maharat Nakhon Ratchasima Hospital","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2026,1,24]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Single-inhaler triple therapy (SITT) is known to be a cost-effective intervention for chronic obstructive pulmonary disease (COPD)<\/jats:p>\n                    <jats:p>in Western countries, but there is no such evidence for resource-limited countries. This study aimed to evaluate the cost-utility of SITT compared with multiple inhaler triple therapy (MITT) for COPD in Thailand.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov model with a lifetime horizon from a societal perspective was conducted with seven health states, including moderate, severe and very severe, with and without acute exacerbation (AE) and death. Two SITTs, fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) and budesonide\/glycopyrrolate\/formoterol (BUD\/GLY\/FOR), were compared with MITT (salmeterol\/fluticasone propionate with tiotropium (SAL\/FP+TIO). A comprehensive literature review was performed to identify inputs. A quality-adjusted life year (QALY) and incremental cost-effectiveness ratio (ICER) were calculated. A series of sensitivity analyses was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>FF\/UMEC\/VI could improve QALY by 0.014 with an increased lifetime cost of 25\u2009649 Thai baht (THB) ($727) compared with SAL\/FP+TIO. In contrast, BUD\/GLY\/FOR had a lower QALY of \u22120.007 with an increased total lifetime cost of 34,151 THB ($968). The ICER for FF\/UMEC\/VI was 1,899,408 THB\/QALY ($53,823), while BUD\/GLY\/FOR was dominated by SAL\/FP+TIO. Probabilistic sensitivity analysis indicated that FF\/UMEC\/VI had a 1.1% chance of being cost-effective at the threshold of 160,000 THB ($4,533). We found that a 30% reduction in FF\/UMEC\/VI price could lead to a cost-effective option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study indicated that SITTs are not cost-effective at the current price compared with the current MITT for COPD treatment. However, FF\/UMEC\/VI could be a promising option, with an approximately 30% price reduction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2025-003619","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:35:19Z","timestamp":1770906919000},"page":"e003619","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Economic evaluation of single-inhaler triple therapy for chronic obstructive pulmonary disease in Thailand"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6981-1771","authenticated-orcid":false,"given":"Piyameth","family":"Dilokthornsakul","sequence":"first","affiliation":[{"name":"Center for Medical and Health Technology Assessment (CM-HTA), Department of Pharmaceutical Care, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyawat","family":"Dilokthornsakul","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand"},{"name":"Depatment of Pharmacy, Omkoi hospital, Omkoi, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bunchai","family":"Chongmelaxme","sequence":"additional","affiliation":[{"name":"Social and Administrative Pharmacy Department, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuchit","family":"Niyompattama","sequence":"additional","affiliation":[{"name":"Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"2026021206351151000_13.1.e003619.1","doi-asserted-by":"crossref","DOI":"10.1038\/s41533-023-00349-4","article-title":"Gold 2023: Highlights for primary care","volume":"33","author":"Agust\u00ed","year":"2023","journal-title":"NPJ Prim Care Respir Med"},{"key":"2026021206351151000_13.1.e003619.2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-2600(21)00511-7","article-title":"Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis","volume":"10","author":"Adeloye","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026021206351151000_13.1.e003619.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069679","article-title":"Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019","volume":"378","author":"Safiri","year":"2022","journal-title":"BMJ"},{"key":"2026021206351151000_13.1.e003619.4","unstructured":"Global Initiative for Chronic Obstructive Lung Disease . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2025 report). 2024."},{"key":"2026021206351151000_13.1.e003619.5","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00950-2020","article-title":"INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice","volume":"7","author":"Halpin","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026021206351151000_13.1.e003619.6","doi-asserted-by":"crossref","first-page":"1147985","DOI":"10.3389\/fphar.2023.1147985","article-title":"Comparison of treatment persistence, adherence, and risk of exacerbation in patients with COPD treated with single-inhaler versus multiple-inhaler triple therapy: A prospective observational study in China","volume":"14","author":"Lin","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026021206351151000_13.1.e003619.7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2023-001890","article-title":"Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study","volume":"11","author":"Rothnie","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"2026021206351151000_13.1.e003619.8","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.2147\/COPD.S370577","article-title":"Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial","volume":"17","author":"Halpin","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026021206351151000_13.1.e003619.9","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.2147\/COPD.S460903","article-title":"Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study","volume":"19","author":"Vogelmeier","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026021206351151000_13.1.e003619.10","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.chest.2022.06.033","article-title":"Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain","volume":"162","author":"Alc\u00e1zar-Navarrete","year":"2022","journal-title":"Chest"},{"key":"2026021206351151000_13.1.e003619.11","doi-asserted-by":"crossref","first-page":"701","DOI":"10.35755\/jmedassocthai.2024.9.701-707-889","article-title":"Risk Factors Associated with Exacerbation Frequency in Chronic Obstructive Pulmonary Disease","volume":"107","author":"Srirojanakul","year":"2024","journal-title":"J Med Assoc Thai"},{"key":"2026021206351151000_13.1.e003619.12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/1874944502013010105","article-title":"The Factors Predicting the Health-Related Quality of Life Among Persons with Chronic Obstructive Pulmonary Disease in Public Health Region 4, Thailand: A Mixed-Methods Study","volume":"13","author":"Wangsom","year":"2020","journal-title":"TOPHJ"},{"key":"2026021206351151000_13.1.e003619.13","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00333-2021","article-title":"Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial","volume":"8","author":"Martin","year":"2022","journal-title":"ERJ Open Res"},{"key":"2026021206351151000_13.1.e003619.14","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02231-0"},{"key":"2026021206351151000_13.1.e003619.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909883"},{"key":"2026021206351151000_13.1.e003619.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713901"},{"key":"2026021206351151000_13.1.e003619.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080409","article-title":"Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study","volume":"387","author":"Feldman","year":"2024","journal-title":"BMJ"},{"key":"2026021206351151000_13.1.e003619.18","unstructured":"World Health Organization . Global health observatory data repository. Geneva, Switzerland, 2020. Available: https:\/\/apps.who.int\/gho\/data\/?theme=main&vid=61640"},{"key":"2026021206351151000_13.1.e003619.19","doi-asserted-by":"crossref","first-page":"106471","DOI":"10.1016\/j.rmed.2021.106471","article-title":"Mortality risk attributable to classification of chronic obstructive pulmonary disease and reduced lung function: A 21-year longitudinal cohort study","volume":"184","author":"Guo","year":"2021","journal-title":"Respir Med"},{"key":"2026021206351151000_13.1.e003619.20","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-3-56","article-title":"Health-related quality of life is related to COPD disease severity","volume":"3","author":"St\u00e5hl","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"2026021206351151000_13.1.e003619.21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/add.13166","article-title":"Cost-effectiveness analysis of clinical smoking cessation interventions in Thailand","volume":"111","author":"Tosanguan","year":"2016","journal-title":"Addiction"},{"key":"2026021206351151000_13.1.e003619.22","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008930521566"},{"key":"2026021206351151000_13.1.e003619.23","unstructured":"Riewpaiboon A , Yongkong S , Patanaphesaj J , et al . Cost estimation. In: Pannarunothai S , Pilasant S , Saengsri W , eds. Handbook of health technology assessment for Thailand (revised edition; 2019). Nonthaburi, Thailand: Health Intervention and Technology Assessment Program (HITAP), 2021."},{"key":"2026021206351151000_13.1.e003619.24","unstructured":"Drug and Medical Supply Information Center, Ministry of Public Health . Reference Purchasing Price (Drug). Nonthaburi, Thailand, 2025. Available: https:\/\/dmsic.moph.go.th\/index\/drugsearch\/1 [accessed 10 Apr 2025]."},{"key":"2026021206351151000_13.1.e003619.25","first-page":"58","article-title":"Cost of illness for chronic obstructive pulmonary disease","volume":"11","author":"Rodthong","year":"2015","journal-title":"Isan J Pharm Sci"},{"key":"2026021206351151000_13.1.e003619.26","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004090","article-title":"Burden of respiratory disease in Thailand: Results from the APBORD observational study","volume":"95","author":"Thanaviratananich","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2026021206351151000_13.1.e003619.27","unstructured":"Health Administration Division, Ministry of Public Health . CMI@MoPH. Nonthaburi, Thailand: Health Administration Division, Ministry of Public Health; 2025. Available: https:\/\/cmi.moph.go.th\/report\/spcl\/index?menu_id=15 [Accessed 4 Jul 2025]."},{"key":"2026021206351151000_13.1.e003619.28","unstructured":"Riewpaiboon A . Standard Cost List. Nonthaburi, Thailand: Health Intevention and Technology Assessment Program (HITAP), Ministry of Public Health, 2009. Available: https:\/\/costingmenu.hitap.net"},{"key":"2026021206351151000_13.1.e003619.29","unstructured":"Bank of Thailand . Currency Exchange. Bangkok, Thailand, 2025. Available: https:\/\/app.bot.or.th\/BTWS_STAT\/statistics\/BOTWEBSTAT.aspx?reportID=123&language=TH [accessed 3 May 2025]."},{"key":"2026021206351151000_13.1.e003619.30","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.2147\/COPD.S370540","article-title":"Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting","volume":"17","author":"Halpin","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026021206351151000_13.1.e003619.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2023-001964","article-title":"Medication adherence to inhalation therapy and the risk of COPD exacerbations: a systematic review with meta-analysis","volume":"11","author":"Vauterin","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"2026021206351151000_13.1.e003619.32","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1080\/13696998.2023.2269748","article-title":"A cost-effectiveness analysis of national smoking cessation services among chronic obstructive pulmonary disease patients in Thailand","volume":"26","author":"Prasitwarachot","year":"2023","journal-title":"J Med Econ"},{"key":"2026021206351151000_13.1.e003619.33","first-page":"71","article-title":"A cost-utility study of smoking cessation interventions for patients with chronic obstructive pulmonary disease in Thailand","volume":"102","author":"Kongsakon","year":"2019","journal-title":"J Med Assoc Thai"},{"key":"2026021206351151000_13.1.e003619.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916046"},{"key":"2026021206351151000_13.1.e003619.35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s41030-025-00306-1","article-title":"Clinically Important Improvements and Disease Stability with Fluticasone Furoate\/Umeclidinium\/Vilanterol Once-Daily Single-Inhaler Triple Therapy in the ELLITHE Trial: A Post Hoc Responder Analysis","volume":"11","author":"Beeh","year":"2025","journal-title":"Pulm Ther"},{"key":"2026021206351151000_13.1.e003619.36","first-page":"205","article-title":"Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population","volume":"25","author":"Wallace","year":"2019","journal-title":"J Manag Care Spec Pharm"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2025-003619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:35:24Z","timestamp":1770906924000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2025-003619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,12]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bmjresp-2025-003619"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2025-003619","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}